Dixon MRI Imaging Histology for Predicting Postoperative Infection in Posterior Lumbar Fusion for Myasthenia Gravis
Launched by THE FIRST PEOPLE'S HOSPITAL OF YUNNAN · Jan 28, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special type of MRI called Dixon MRI can help predict the risk of infections after surgery for patients with myasthenia gravis who are undergoing a procedure known as posterior lumbar fusion. This surgery is often needed for issues in the lower back, but it can come with risks, especially if a patient has a condition called sarcopenia, which means they have less muscle mass and strength. The researchers believe that by using Dixon MRI imaging, they can get a better understanding of a patient’s muscle condition, helping to identify those who might be at higher risk for infections after their surgery.
To participate in this study, patients must be at least 18 years old and have had a Dixon MRI scan within two weeks before their surgery. They should also have sarcopenia as defined by specific medical guidelines and should be able to give their consent to participate. However, individuals with certain health issues, like serious heart or kidney problems, or those who cannot undergo an MRI due to implanted devices, will not be eligible. If you decide to participate, you can expect close monitoring and detailed follow-up after your surgery, as the researchers aim to improve safety and outcomes for patients undergoing this type of procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients over 18 years of age.
- • Inclusion of patients with sarcopenia is subject to the definition and diagnostic criteria of the European Consensus on Definition and Diagnosis of Sarcopenia.
- • The patient underwent posterior lumbar fusion and had a Dixon MRI scan within 2 weeks prior to surgery.
- • Patients were able to understand the purpose and procedures of the study and were willing to sign an informed consent form.
- • The patient's clinical consultation and follow-up information was complete.
- Exclusion Criteria:
- • The patient has contraindications to MRI, such as implanted metal devices (e.g., pacemakers) or severe claustrophobia.
- • Patients with serious other medical conditions, such as heart disease, kidney disease or liver disease, which may affect their post-operative recovery.
- • Patients have known immune system disorders or are on immunosuppressive therapy, which may affect their risk of infection.
- • The patient has had other spinal surgery within the last 6 months.
About The First People's Hospital Of Yunnan
The First People's Hospital of Yunnan is a prominent healthcare institution located in Kunming, China, dedicated to advancing medical research and improving patient care. As a leading clinical trial sponsor, the hospital is committed to conducting innovative and ethically sound research that contributes to the development of new therapies and medical interventions. With a multidisciplinary team of experienced researchers and clinicians, the First People's Hospital of Yunnan leverages its state-of-the-art facilities and comprehensive patient databases to facilitate high-quality clinical trials. The institution prioritizes collaboration with global partners to enhance healthcare outcomes and drive medical advancements in a variety of therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported